In addition, gefitinib also enhanced an efficacy of anti-PD-1 antibody treatment in other syngeneic animal models such as EMT6 (mouse breast cancer cells) and CT26 (mouse colon cancer cells; Supplementary Fig. 9e–g). Here, DDX53 is linked to breast carcinoma.